Pathogen reduction and HLA alloimmunization: more questions than answers

Transfusion

Volumn 59, Issue 3, 2019, Pages 1152-1155

  Stolla, Moritz ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; CD69 ANTIGEN; HLA ANTIBODY; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LYMPHOCYTE ANTIBODY; RIBOFLAVIN; THROMBOCYTE ANTIBODY; ALLOANTIBODY;

ALLOIMMUNIZATION; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; BLEEDING; CARDIAC GRAFT REJECTION; CELL SURVIVAL; GAMMA IRRADIATION; HEART TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; NONHUMAN; NOTE; PATHOGEN REDUCTION; PHOTOPHERESIS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROCONVERSION; THROMBOCYTE TRANSFUSION; TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; BLOOD TRANSFUSION;

BLOOD TRANSFUSION; HUMANS; ISOANTIBODIES; PLATELET TRANSFUSION;

EID: 85061967173     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.15211     Document Type: Note

References (25)

1. Goodrich RP, Edrich RA, Li J, et al. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006;35:5-17.
2. Asano H, Lee CY, Fox-Talbot K, et al. Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Transplantation 2007;84:1174-82.
3. −/− double knockout mice. Transfusion 2006;46:1553-60.
4. Fast LD, Dileone G, Li J, et al. Functional inactivation of white blood cells by Mirasol treatment. Transfusion 2006;46:642-8.
5. Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997;337:1861-9.
6. Saris A, Kerkhoffs JL, Norris PJ, et al. The role of pathogen-reduced platelet transfusions on HLA alloimmunization in hemato-oncological patients. Transfusion 2019;59:470-81.
7. van der Meer PF, Ypma PF, van Geloven N, et al. Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial. Blood 2018;132:223-31.
8. Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the seventh special issue. J Clin Apher 2016;31:149-62.
9. Fast LD. The effect of exposing murine splenocytes to UVB light, psoralen plus UVA light, or gamma-irradiation on in vitro and in vivo immune responses. Transfusion 2003;43:576-83.
10. Fast LD, DiLeone G, Edson CM, et al. PEN110 treatment functionally inactivates the PBMNCs present in RBC units: comparison to the effects of exposure to gamma irradiation. Transfusion 2002;42:1318-25.
11. Jackman RP, Heitman JW, Marschner S, et al. Understanding loss of donor white blood cell immunogenicity after pathogen reduction: mechanisms of action in ultraviolet illumination and riboflavin treatment. Transfusion 2009;49:2686-99.
12. Jackman RP, Muench MO, Inglis H, et al. Reduced MHC alloimmunization and partial tolerance protection with pathogen reduction of whole blood. Transfusion 2017;57:337-48.
13. Fast LD, Nevola M, Reddy HL, et al. Inactivation of leukocytes in whole blood treated with the Mirasol® System in comparison to gamma-irradiation. Transfusion 2011;51:1397-404.
14. Jackman RP, Muench MO, Heitman JW, et al. Immune modulation and lack of alloimmunization following transfusion with pathogen-reduced platelets in mice. Transfusion 2013;53:2697-709.
15. Slichter SJ, Pellham E, Bailey SL, et al. Leukofiltration plus pathogen reduction prevents alloimmune platelet refractoriness in a dog transfusion model. Blood 2017;130:1052-61.
16. Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010;50:2362-75.
17. Ambruso DR, Thurman G, Marschner S, et al. Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates. Transfusion 2009;49:2631-6.
18. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004;104:1534-41.
19. van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101:2426-33.
20. Lucidi CA, Takahira RK, Gerlach JA, et al. Flow cytometric assessment of canine erythrocytes and platelets for dog erythrocyte antigen 1.1. Vet Clin Pathol 2011;40:435-43.
21. Diehl R, Ferrara F, Muller C, et al. Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches. Cell Mol Immunol 2017;14:146-79.
22. Bartman C, Chong AS, Alegre ML. The influence of the microbiota on the immune response to transplantation. Curr Opin Organ Transplant 2015;20:1-7.
23. Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease. Nature 2016;535:75-84.
24. Garban F, Guyard A, Labussiere H, et al. Evaluation of the efficacy of platelets treated with pathogen reduction process study G. Comparison of the hemostatic efficacy of pathogen-reduced platelets vs untreated platelets in patients with thrombocytopenia and malignant hematologic diseases: a randomized clinical trial. JAMA Oncol 2018;4:468-75.
25. Terumo B, Biomedical Advanced R, Development A. Efficacy of Mirasol-treated Apheresis Platelets in Patients With Hypoproliferative Thrombocytopenia, 2021. https://clinicaltrials.gov/ct2/show/NCT02964325.